drugset / Trial / NCT05273242
Add-on Study on WHO Solidarity Trial Plus for COVID-19 in Nepal
RandomizedParallel-groupOpen-labelTreatment
Summary
Proposal for Sub-Study to be conducted with the WHO Solidarity Plus Trial: Apart from the data been collected as per the WHO Solidarity Trial Plus protocol, Nepal Health Research Council will conduct a sub-study to evaluate some components which are felt to be important in the local context but have not been included as part of the Solidarity Trial Plus. Rather that conducting a separate study, the following components can be evaluated by collecting additional data as a part of sub-study in the local context.
Timeline
- Start
- 2021-12-06
- Primary completion
- 2022-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Artesunate | Small molecule | 2.4 mg/kg | Intravenous |
| Subject | Imatinib | Small molecule | 400 mg | Oral |
| Subject | Infliximab | Monoclonal antibody | 5 mg/kg | Intravenous |